Scientific Reports (Nov 2023)

ALS/FTD-associated mutation in cyclin F inhibits ER-Golgi trafficking, inducing ER stress, ERAD and Golgi fragmentation

  • Audrey M. G. Ragagnin,
  • Vinod Sundaramoorthy,
  • Fabiha Farzana,
  • Shashi Gautam,
  • Sayanthooran Saravanabavan,
  • Zeinab Takalloo,
  • Prachi Mehta,
  • Dzung Do-Ha,
  • Sonam Parakh,
  • Sina Shadfar,
  • Julie Hunter,
  • Marta Vidal,
  • Cyril J. Jagaraj,
  • Mariana Brocardo,
  • Anna Konopka,
  • Shu Yang,
  • Stephanie L. Rayner,
  • Kelly L. Williams,
  • Ian P. Blair,
  • Roger S. Chung,
  • Albert Lee,
  • Lezanne Ooi,
  • Julie D. Atkin

DOI
https://doi.org/10.1038/s41598-023-46802-9
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 20

Abstract

Read online

Abstract Amyotrophic lateral sclerosis (ALS) is a severely debilitating neurodegenerative condition that is part of the same disease spectrum as frontotemporal dementia (FTD). Mutations in the CCNF gene, encoding cyclin F, are present in both sporadic and familial ALS and FTD. However, the pathophysiological mechanisms underlying neurodegeneration remain unclear. Proper functioning of the endoplasmic reticulum (ER) and Golgi apparatus compartments is essential for normal physiological activities and to maintain cellular viability. Here, we demonstrate that ALS/FTD-associated variant cyclin FS621G inhibits secretory protein transport from the ER to Golgi apparatus, by a mechanism involving dysregulation of COPII vesicles at ER exit sites. Consistent with this finding, cyclin FS621G also induces fragmentation of the Golgi apparatus and activates ER stress, ER-associated degradation, and apoptosis. Induction of Golgi fragmentation and ER stress were confirmed with a second ALS/FTD variant cyclin FS195R, and in cortical primary neurons. Hence, this study provides novel insights into pathogenic mechanisms associated with ALS/FTD-variant cyclin F, involving perturbations to both secretory protein trafficking and ER-Golgi homeostasis.